# Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

> **NCT01248117** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Retina Consultants of Hawaii** · enrollment: 20 (estimated)

## Conditions studied

- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** ranibizumab 2.0mg

## Key facts

- **NCT ID:** NCT01248117
- **Lead sponsor:** Retina Consultants of Hawaii
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2012-12
- **Final completion:** 2013-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248117, "Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01248117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*